Editor’s note: This is a developing news story. Please check back soon for updates.
The FDA approved Tryptyr to treat the signs and symptoms of dry eye disease, according to a press release from Alcon.
Tryptyr (acoltremon ophthalmic solution 0.003%), formerly known as AR-15512, is an agonist of transient receptor potential melastatin 8 thermoreceptors that stimulates corneal sensory nerves and increases natural tear production, although its exact mechanism of action in dry eye disease is unknown, according to the release.
“Many of my patients continue to face frustrating challenges